Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD). Pamiparib has good bio...

Full description

Bibliographic Details
Main Authors: Yao Xiong, Yin Guo, Ye Liu, Hexiang Wang, Wenfeng Gong, Yong Liu, Xing Wang, Yajuan Gao, Fenglong Yu, Dan Su, Fan Wang, Yutong Zhu, Yuan Zhao, Yiyuan Wu, Zhen Qin, Xuebing Sun, Bo Ren, Bin Jiang, Wei Jin, Zhirong Shen, Zhiyu Tang, Xiaomin Song, Lai Wang, Xuesong Liu, Changyou Zhou, Beibei Jiang
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Pamiparib
PARP
TMZ
Brain penetration
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558620301317

Internet

http://www.sciencedirect.com/science/article/pii/S1476558620301317

Similar Items